Applying global lessons to protect abortion access in the United States

Terry McGovern,Mary Favier,Laura Gil,Bonsitu Kitaba-Gaviglio,Clarisa Bencomo,Ira Memaj,Samantha Garbers,Malia Maier
DOI: https://doi.org/10.1136/bmj-2022-073833
2024-01-03
BMJ
Abstract:Since the US Supreme Court overturned Roe v Wade in 2022, eliminating the federal constitutional right to an abortion, the introduction of state laws and policies has made the legal and healthcare landscape more challenging. Twenty states have banned or severely restricted abortion care,1 and recent legislation is restricting access to abortion medication as well as abortion services, with Wyoming becoming the first state explicitly to ban the use of abortion medication.2In response, US abortion rights advocates have pushed to extend federal protections and the federal government has taken important steps to expand and protect access to medication abortion. These efforts have focused on strengthening executive branch rules and guidance because the lack of a pro-abortion majority in Congress prevents legislation being passed to protect abortion. In January 2023, the US Food and Drug Administration eliminated a requirement that mifepristone, the most common form of medication abortion, be dispensed in...
medicine, general & internal
What problem does this paper attempt to address?